Cancer Statistics, 2010, CA: A Cancer Journal for Clinicians, vol.60, issue.5, pp.277-300, 2010. ,
DOI : 10.3322/caac.20073
Is Age a??Risk Factor of Postoperative Complications in Colorectal Cancer?, Polish Journal of Surgery, vol.85, issue.9, pp.491-495, 2013. ,
DOI : 10.2478/pjs-2013-0076
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology, The Lancet Oncology, vol.8, issue.12, pp.1101-1115, 2007. ,
DOI : 10.1016/S1470-2045(07)70378-9
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials, New England Journal of Medicine, vol.341, issue.27, pp.2061-2067, 1999. ,
DOI : 10.1056/NEJM199912303412706
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials, Journal of Clinical Oncology, vol.21, issue.7, pp.1383-1389, 2003. ,
DOI : 10.1200/JCO.2003.08.010
Pharmacokinetics of drugs in the elderly, J R Soc Med, vol.87, pp.2-4, 1994. ,
When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly, Experimental Gerontology, vol.38, issue.8, pp.843-853, 2003. ,
DOI : 10.1016/S0531-5565(03)00133-5
Vision of the Future: Capecitabine, The Oncologist, vol.6, issue.90004, pp.35-39, 2001. ,
DOI : 10.1634/theoncologist.6-suppl_4-35
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue, European Journal of Cancer, vol.34, issue.8, pp.1274-1281, 1998. ,
DOI : 10.1016/S0959-8049(98)00058-6
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients, British Journal of Clinical Pharmacology, vol.16, issue.3, pp.252-263, 2003. ,
DOI : 10.1046/j.1365-2125.2003.01765.x
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug, Investigational New Drugs, vol.17, issue.1, pp.49-56, 1999. ,
DOI : 10.1023/A:1006263400888
Clinical Pharmacokinetics of Capecitabine, Clinical Pharmacokinetics, vol.19, issue.12, pp.85-104, 2001. ,
DOI : 10.2165/00003088-200140020-00002
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030), British Journal of Cancer, vol.6, issue.7, pp.1744-1749, 2013. ,
DOI : 10.1124/dmd.109.028209
Population pharmacokinetic analysis of the major metabolites of capecitabine, Journal of Pharmacokinetics and Pharmacodynamics, vol.29, issue.1, pp.25-47, 2002. ,
DOI : 10.1023/A:1015716617967
Pharmacokinetic Modelling of 5-FU Production from Capecitabine???A Population Study in 40 Adult Patients with Metastatic Cancer, Journal of Pharmacokinetics and Pharmacodynamics, vol.52, issue.5-6, pp.817-833, 2005. ,
DOI : 10.1007/s10928-005-0018-2
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer, Journal of Geriatric Oncology, vol.4, issue.2, pp.114-121, 2013. ,
DOI : 10.1016/j.jgo.2013.01.001
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, The Lancet Oncology, vol.14, issue.11, pp.1077-1085, 2013. ,
DOI : 10.1016/S1470-2045(13)70154-2
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907, Breast Cancer Research and Treatment, vol.14, issue.1, pp.607-616, 2013. ,
DOI : 10.1007/s10549-013-2562-6
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression, Clin Pharmacol, vol.83, pp.829-839, 2008. ,
NONMEM User's Guide; NONMEM project group, University of California Prediction of creatinine clearance from serum creatinine, pp.31-41, 1976. ,
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis, European Journal of Cancer, vol.34, issue.1, pp.92-97, 1998. ,
DOI : 10.1016/S0959-8049(97)00345-6
A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models, Computer Methods and Programs in Biomedicine, vol.59, issue.1, pp.19-29, 1999. ,
DOI : 10.1016/S0169-2607(98)00098-4
Dose and time dependencies of 5-fluorouracil pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.68, issue.3, pp.270-279, 2000. ,
DOI : 10.1067/mcp.2000.109352
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinoma, Clin Cancer Res, vol.4, pp.2039-2045, 1998. ,
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients, Cancer Chemotherapy and Pharmacology, vol.49, issue.3, pp.225-234, 2002. ,
DOI : 10.1007/s00280-001-0408-0
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer, Journal of Clinical Oncology, vol.17, issue.2, pp.485-493, 1999. ,
DOI : 10.1200/JCO.1999.17.2.485
Incidence and severity of handfoot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience, Cancer, vol.20, pp.3-10, 2002. ,
Palmar???plantar erythrodysesthesia due to docetaxel???capecitabine therapy is treated with vitamin E without dose reduction, The Breast, vol.15, issue.3, pp.414-424, 2006. ,
DOI : 10.1016/j.breast.2005.07.007
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer., Journal of Clinical Oncology, vol.16, issue.1, pp.187-196, 1998. ,
DOI : 10.1200/JCO.1998.16.1.187